Estradiol cypionate

Medical uses

Main article: Estradiol (medication)#Medical uses, High-dose estrogen

The medical uses of estradiol cypionate are the same as those of estradiol and other estrogens. Examples of indications for the drug include hormone therapy and hormonal contraception. In regard to the latter, estradiol cypionate has been used in combination with medroxyprogesterone acetate as a combined injectable contraceptive. Along with estradiol valerate, estradiol undecylate, and estradiol benzoate, estradiol cypionate is used as a form of high-dose estrogen therapy in feminizing hormone therapy for transgender women. The medication has been used to induce puberty in girls with delayed puberty due to hypogonadism.

Estradiol cypionate is usually used at a dosage of 1 to 5 mg by intramuscular injection every 3 to 4 weeks in the treatment of menopausal symptoms such as hot flashes and vaginal atrophy, at a dosage of 1.5 to 2 mg by intramuscular injection once a month in the treatment of female hypoestrogenism due to hypogonadism, and at a dosage of 2 to 10 mg by intramuscular injection once every 1 or 2 weeks for hormone therapy in transgender women. The doses used to induce puberty in girls are 0.2 to 2.5 mg per month, gradually increased over a period of 4 years.

Available forms

Estradiol cypionate is and has been available as an oil solution for intramuscular injection provided in vials and ampoules at concentrations of 1, 3, and 5 mg/mL (and containing 5, 10, 15, 25, or 50 mg estradiol cypionate total). The 1 and 3 mg/mL concentrations (containing 5 and 15 mg estradiol cypionate total) have been discontinued in the United States, but the 5 mg/mL concentration (containing 25 mg estradiol cypionate total) remains available. Aside from estradiol cypionate, the only other injectable estrogen formulations that remain available in the United States are estradiol valerate (10 mg/mL, 20 mg/mL, and 40 mg/mL in oil) and conjugated estrogens (25 mg/vial in solution).

In addition to single-drug formulations, estradiol cypionate has been marketed in combination with medroxyprogesterone acetate as a microcrystalline aqueous suspension (brand name Lunelle) and in combination with testosterone cypionate as an oil solution (brand name Depo-Testadiol).

Contraindications

Contraindications of estrogens include coagulation problems, cardiovascular diseases, liver disease, and certain hormone-sensitive cancers such as breast cancer and endometrial cancer, among others.

Side effects

Main article: Estradiol (medication)#Side effects

The side effects of estradiol cypionate are the same as those of estradiol. Examples of such side effects include breast tenderness and enlargement, nausea, vomiting, bloating, edema, headache, migraine, and melasma. High-dose estrogen therapy with estradiol cypionate injections may also cause an increased risk of thromboembolism, changes in blood lipid profile, increased insulin resistance, and increased levels of prolactin.

Overdose

Symptoms of estrogen overdosage may include nausea, vomiting, bloating, increased weight, water retention, breast tenderness, vaginal discharge, heavy legs, and leg cramps. These side effects can be diminished by reducing the estrogen dosage.

Interactions

Inhibitors and inducers of cytochrome P450 may influence the metabolism of estradiol and by extension circulating estradiol levels.

Pharmacology

Pharmacodynamics

Estradiol cypionate is an estradiol ester, or a prodrug of estradiol. As such, it is an estrogen, or an agonist of the estrogen receptors. The affinity of estradiol valerate for the estrogen receptor has been reported to be 50 times less than that of estradiol, and estradiol valerate and estradiol cypionate have been found to possess similar affinity for the estrogen receptor. Both estradiol cypionate and estradiol valerate are rapidly cleaved into estradiol in the body, and estradiol valerate has been found to be unable to reach target tissues in any concentration of significance. As such, estradiol valerate is regarded as essentially inactive in terms of estrogenic effect itself, acting solely as a prodrug to estradiol, and estradiol cypionate is described as a prodrug of estradiol similarly. Estradiol cypionate is of about 46% higher molecular weight than estradiol due to the presence of its C17β cypionate ester, and contains about 69% of the amount of estradiol by weight. Because estradiol cypionate is a prodrug of estradiol, it is considered to be a natural and bioidentical form of estrogen.

Effects on liver protein synthesis

A study compared the combination of 5 mg estradiol cypionate and 25 mg medroxyprogesterone acetate as a combined injectable contraceptive (which has been associated with peak estradiol levels of around 300 pg/mL) with an ethinylestradiol-containing combined birth control pill and found that whereas the birth control pill produced significant changes in coagulation parameters, there were no significant prothrombotic effects of the combined injectable contraceptive on levels of fibrinogen, factors VII and X, plasminogen, or the activated prothrombin time. As such, it appears that similarly to depot medroxyprogesterone acetate, combined injectable contraceptives with 5 mg estradiol cypionate and 25 mg medroxyprogesterone acetate have less or no procoagulant effect relative to combined birth control pills.

Pharmacokinetics

Intramuscular injection

In contrast to oral administration, which is associated with very low bioavailability (

A single intramuscular injection of 5 mg estradiol cypionate has been found to result in peak circulating concentrations of 338 pg/mL estradiol and 145 pg/mL estrone, which occurred at about 4 and 5 days post-injection, respectively (see right table). Compared to two other commonly used estradiol esters (which were also assessed in the study), estradiol cypionate had the longest duration, at approximately 11 days, whereas estradiol benzoate and estradiol valerate were found to last for 4 to 5 days and 7 to 8 days, respectively. This is because estradiol cypionate has a more extensive fatty acid chain and in relation to this is comparatively more lipophilic. For a given estradiol ester, the longer or more extensive the fatty acid chain is, the more lipophilic, longer-lasting, and more uniform/plateau-like the resultant levels of estradiol are as well as the lower the peak/maximal levels are (and hence less spike-like).

Estradiol cypionate/medroxyprogesterone acetate (brand names Lunelle, Cyclofem) is a combined injectable contraceptive containing 5 mg estradiol cypionate and 25 mg medroxyprogesterone acetate in microcrystalline aqueous suspension for once-monthly intramuscular administration. With this formulations, estradiol levels peak 2 to 3 days post-injection with average maximal circulating levels of about 250 pg/mL. The elimination half-life of estradiol with these formulations is 8.4 to 10.1 days, and circulating estradiol levels return to a baseline of about 50 pg/mL approximately 14 to 24 days post-injection.{{cite web|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20874lbl.pdf|archive-url=https://web.archive.org/web/20170210040444/http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20874lbl.pdf|url-status=dead|archive-date=February 10, 2017|access-date=21 April 2023|website=accessdata.fda.gov

| File:Estradiol levels after a single subcutaneous or intramuscular injection of 5 mg estradiol cypionate.png | Estradiol levels after subcutaneous (s.c.) or intramuscular (i.m.) injection of 5 mg estradiol cypionate in aqueous suspension. Assays were performed using enzyme immunoassay. Source was Sierra-Ramírez et al. (2011).

| File:Estradiol levels at steady state with intramuscular injections of 5 mg estradiol cypionate per month in premenopausal women.png | Estradiol levels at steady state (after the 3rd injection) with intramuscular injections of aqueous suspensions of 5 mg estradiol cypionate per month in premenopausal women. Assays were performed using enzyme immunoassay and . Sources were Rahimy et al. (1999) and Thurman et al. (2013).

| File:Estradiol levels after a single intramuscular injection of 1.0 to 2.0-mg estradiol cypionate in hypogonadal girls.png | Estradiol levels after a single intramuscular injection of 1.0 to 2.0 mg (average 1.67 mg) of estradiol cypionate in oil (Depo-Estradiol) in hypogonadal girls. Assays were performed using radioimmunoassay with chromatographic separation. Sources were Rosenfield et al. (1973, 1974).

| File:Estradiol levels after a single 5 mg intramuscular injection of estradiol esters.png | Estradiol levels after single intramuscular injections of 5 mg of different estradiol esters in oil in premenopausal women. Assays were performed using radioimmunoassay with chromatographic separation. Source was Oriowo et al. (1980).

| File:Idealized curves of estradiol levels after injection of different estradiol esters in women.png | Simplified curves of estradiol levels after injection of different estradiol esters in oil solution in women. Source was Garza-Flores (1994).

| File:Estradiol cypionate levels after a single intramuscular injection of 5 mg microcrystalline estradiol cypionate in aqueous suspension in women.png | Estradiol cypionate levels after a single injection of 5 mg microcrystalline estradiol cypionate in aqueous suspension in women. Assays were performed using . Source was Martins et al. (2019).

| File:Vaginal cornification with a single intramuscular injection of different estradiol esters in women.png | Vaginal cornification with a single intramuscular injection of different estradiol esters in oil solution in women. Source was Schwartz & Soule (1955).

Subcutaneous injection

Estradiol cypionate in a microcrystalline aqueous suspension has been found to have equivalent effectiveness and virtually identical pharmacokinetics when administered by subcutaneous injection versus intramuscular injection. However, subcutaneous injection is considered to be easier and less painful relative to intramuscular injection, and for these reasons, may result in comparatively greater satisfaction and compliance.

Chemistry

Estradiol cypionate is a synthetic estrane steroid and the C17β cyclopentylpropionate (cypionate) fatty acid ester of estradiol. It is also known as estra-1,3,5(10)-triene-3,17β-diol 17β-cyclopentylpropionate. Other common esters of estradiol in use include estradiol valerate, estradiol enantate, and estradiol acetate, the former two of which are C17β esters of estradiol similarly to estradiol cypionate and the latter of which is the C3 acetate ester of estradiol.

The experimental octanol/water partition coefficient (logP) of estradiol cypionate is 6.9.

History

Estradiol cypionate was patented by Upjohn in 1952, with a priority date of 1951. It was first introduced for medical use by Upjohn in 1952 under the brand name Depo-Estradiol in the United States. Subsequently, it was also marketed in other countries such as European countries and Japan. The first clinical reports of estradiol cypionate were published in 1952 and thereafter. It was initially known as estradiol cyclopentylpropionate (ECP), and did not become known as estradiol cypionate until over a decade later in the mid-to-late 1960s. Along with estradiol valerate (1954) and estradiol benzoate (1933), estradiol cypionate has become one of the most commonly used esters of estradiol.

When estradiol cypionate was to be combined with medroxyprogesterone acetate as a once-a-month injectable contraceptive, there was a problem in that estradiol cypionate was prepared as an oil solution while medroxyprogesterone acetate was used as a microcrystalline aqueous suspension. This issue was resolved by switching to a microcrystalline aqueous suspension in the case of estradiol cypionate, allowing it to be combined with medroxyprogesterone acetate in a single suspension. As a result, single-drug preparations of estradiol cypionate are oil solutions, while the combination of estradiol cypionate and medroxyprogesterone acetate are microcrystalline aqueous suspensions.

Society and culture

Generic names

Estradiol cypionate is the generic name of the drug and its and . It is also known as estradiol cyclopentylpropionate (ECP).

Brand names

Estradiol cypionate has been marketed under the brand names Cicloestradiolo, D-Est, depGynogen, Depo-Estradiol, Depoestra, Depofemin, Depogen, Dura-Estrin, E-Cypionate, E-Ionate, Estradep, Estro-Cyp, Estrofem, Estroject, Estromed-PA, Estronol, Femovirin, Neoginon Depositum, Oestradiol-Retard, Pertradiol, Spendepiol, and T-E Cypionate, among others.

Availability

Estradiol cypionate is available in the United States. It was previously marketed in Spain and Italy, but was discontinued in these countries and is no longer available in Europe. Estradiol cypionate has mostly been used in the United States, similarly to testosterone cypionate, with both of these medications having been developed by Upjohn, an American pharmaceutical company. Besides the United States, estradiol cypionate has been marketed in France, Germany, Italy, Spain, and Japan, among other countries. Estradiol cypionate for human use is not available in Canada, although it is marketed in several veterinary formulations in this country.

Estradiol cypionate is available in Taiwan in combination with testosterone cypionate. It is also available as a combined injectable contraceptive in combination with medroxyprogesterone acetate in at least 18 countries, mostly in Latin America and Southeast Asia. Estradiol cypionate/testosterone cypionate and estradiol cypionate/medroxyprogesterone acetate were both formerly marketed in the United States, but have been discontinued in this country.

References

References

1. "Estradiol: Uses, Dosage & Side Effects".
2. (June 2013). "Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment". Contraception.
3. (2007). "Clinical Reproductive Medicine and Surgery". Elsevier Health Sciences.
4. (June 2013). "Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics". Contraception.
5. (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception.
6. (1994). "A review of "once-a-month" combined injectable contraceptives". J Obstet Gynaecol (Lahore).
7. (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control". World J Pharm Pharm Sci.
8. (6 December 2012). "Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen". Springer Science & Business Media.
9. (June 2007). "Bioidentical hormone therapy: a review of the evidence". J Womens Health (Larchmt).
10. (1991). "Reproductive endocrinology: physiology, pathophysiology, and clinical management". Saunders.
11. (2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis US.
12. "Estradiol".
13. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration.
14. (January 2009). "New technologies in contraception". BJOG.
15. (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America.
16. (December 2014). "Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults". Pharmacotherapy.
17. (20 May 2016). "Principles of Transgender Medicine and Surgery". Routledge.
18. (1 March 2001). "Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts". Temple University Press.
19. (2006). "Physiologic induction of puberty in Turner syndrome with very low-dose estradiol". International Congress Series.
20. (1 February 1977). "AMA drug evaluations". Publishing Sciences Group.
21. (2014). "Pharmaceutical Substances: Syntheses, Patents and Applications of the most relevant APIs". Thieme.
22. (2001). "Principles and Practice of Endocrinology and Metabolism". Lippincott Williams & Wilkins.
23. Food and Drug Administration. (2011). "Approved Drug Products with Therapeutic Equivalence Evaluations - FDA Orange Book". DrugPatentWatch.com.
24. (22 June 2005). "Current Management of the Menopause". CRC Press.
25. (2001). "Menopause – Andropause: Hormone Replacement Therapy Through the Ages". Krause & Pachernegg: Gablitz.
26. (1976). "The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London". MTP Press Limited.
27. (23 September 2010). "Mayo Clinic Internal Medicine Board Review". OUP USA.
28. (December 2015). "Pharmacotherapy Considerations in the Management of Transgender Patients: A Brief Review". Pharmacotherapy.
29. (September 1990). "Clinical use of oestrogens and progestogens". Maturitas.
30. (February 2001). "Role of cytochrome P450 in estradiol metabolism in vitro". Acta Pharmacol. Sin..
31. (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric.
32. (December 1982). "Pharmacokinetic and pharmacological features of oestradiol valerate". Maturitas.
33. (2000). "Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity". Arterioscler. Thromb. Vasc. Biol..
34. (January 1989). "Actions of an estradiol-17-fatty acid ester in estrogen target tissues of the rat: comparison with other C-17 metabolites and a pharmacological C-17 ester". Endocrinology.
35. (2017). "Frontiers in Gynecological Endocrinology: Pediatric and Adolescent Gynecological Endocrinology". Springer.
36. (December 2000). "Injectable contraception. New and existing options". Obstet. Gynecol. Clin. North Am..
37. (2007). "Medicinal Chemistry". Pearson Education India.
38. (March 1983). "Long-acting contraceptive agents: design of the WHO Chemical Synthesis Programme". Steroids.
39. (15 December 2012). "Progress in Obstetrics and Gynecology--3". Jaypee Brothers Medical Publishers Pvt. Ltd..
40. (October 1999). "Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women". Contraception.
41. (2011). "Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)". Contraception.
42. (October 1999). "Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women". Contraception.
43. (October 1973). "The effects of low doses of depot estradiol and testosterone in teenagers with ovarian failure and Turner's syndrome". J. Clin. Endocrinol. Metab..
44. (December 1974). "The effects of prolonged physiologic estradiol therapy on the maturation of hypogonadal teen-agers". J Pediatr.
45. (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception.
46. (June 2019). "Quantification of estradiol cypionate in plasma by liquid chromatography coupled with tandem mass spectrometry: Application in a pharmacokinetic study in healthy female volunteers". J Pharm Biomed Anal.
47. (July 1955). "Estradiol 17-beta-cyclopentylpropionate, a long-acting estrogen". Am. J. Obstet. Gynecol..
48. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
49. "Estradiol cypionate | C26H36O3 | ChemSpider".
50. (1 January 1988). "Pharmaceutical Manufacturing Encyclopedia". William Andrew.
51. William Andrew Publishing. (22 October 2013). "Pharmaceutical Manufacturing Encyclopedia". Elsevier.
52. Ott, A. C. (1952). U.S. Patent No. 2,611,773. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US2611773A/en
53. (October 1952). "Responses of the vaginal epithelium of postmenopausal women to single doses of estrogens". Journal of Gerontology.
54. (July 1953). "A comparison of the influence of alpha-estradiol dipropionate and of estradiol cyclopentylpropionate on the vaginal mucosa of nonmenstruating and irregularly menstruating women". American Journal of Obstetrics and Gynecology.
55. (October 1953). "Estradiol cyclopentylpropionate: a new, long-acting, injectable estrogen". The Journal of Clinical Endocrinology and Metabolism.
56. (May 1953). "Estradiol 17-cyclopentyl-propionate". Missouri Medicine.
57. (March 1968). "Conception control by monthly injections of medroxyprogesterone suspension and long-acting oestrogen". Journal of Reproduction and Fertility.
58. (1969). "Research and development, market power, and patent policy in ethical drugs". University of Wisconsin--Madison.
59. (1933). "Die Behandlung der Amenorrhöe mit Hohen Dosen der Ovarialhormone". Klinische Wochenschrift.
60. (2009). "Neue Wege der Hormontherapie in der Gynäkologie". Deutsche Medizinische Wochenschrift.
61. (1935). "Commercial Glandular Products". Journal of the American Medical Association.
62. (1994). "Pharmacology of the contraceptive steroids". Raven Press.
63. (2011). "Anabolics". Molecular Nutrition Llc.
64. (25 April 2012). "Drug Product Database online query".
65. (2009). "Martindale: The Complete Drug Reference". Pharmaceutical Press.
66. "Micromedex Products: Please Login".
67. (1 January 1999). "Hormonal Contraception and Post-menopausal Hormonal Therapy". IARC.
68. (2008). "Atlas of Contraception". CRC Press.
69. (2007). "Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy". World Health Organization.
70. (1995). "Still waiting for the contraceptive revolution". Fam Plann Perspect.